Table 24:
Base Case Analysis Results
| Strategy | Average Total Costs, $ | Incremental Cost of LAAC,a $ | Average Total QALYs | Incremental QALYs of LAAC Deviceb | ICER of LAAC Devicec |
|---|---|---|---|---|---|
| Intervention | |||||
| LAAC device | 40,707 | – | 5.66 | – | – |
| Comparator | |||||
| Apixaban | 26,248 | 14,459 | 5.82 | −0.16 | Dominatedd |
| Dabigatran | 25,694 | 15,013 | 5.81 | −0.15 | Dominatedd |
| Rivaroxaban | 30,530 | 10,177 | 5.74 | −0.08 | Dominatedd |
| Warfarin | 24,374 | 16,333 | 5.60 | 0.06 | $272,216/QALY |
Abbreviations: ICER, incremental cost-effectiveness ratio; LAAC, left atrial appendage closure device with delivery system; QALY, quality-adjusted life-year.
a
Incremental costs = average costs (LAAC device) – average costs (comparator).
b
Incremental QALYs = average QALYs (LAAC device) – average QALYs (comparator).
c
ICER = incremental costs ÷ incremental QALYs.
d
Higher costs, lower QALYs.